Literature DB >> 11048895

Cardiovascular disease in diabetes mellitus type 2: a potential role for novel cardiovascular risk factors.

J M Hayden1, P D Reaven.   

Abstract

A major consequence of diabetes mellitus type 2 is the accelerated development of atherosclerosis. Assessment of conventional risk factors such as plasma lipids, lipoproteins and hypertension only partly account for the excessive risk of developing cardiovascular disease in this population. Increasing evidence has emerged suggesting that conditions associated with diabetes mellitus type 2, such as insulin resistance, hyperinsulinemia and hyperglycemia, may also play a significant role in regulating 'novel' cardiovascular risk factors. These factors and their potential roles in the development of atherosclerosis and cardiovascular events are discussed in this review.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11048895     DOI： 10.1097/00041433-200010000-00010

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN： 0957-9672            Impact factor:   4.776


  18 in total

Review 1.  The epidemiology of atherosclerosis and its risk factors among Native Americans.

Authors:  James M Galloway
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

2.  Heart protection study: LDL lowering therapy and cardiovascular outcomes in patients with low cholesterol levels or diabetes.

Authors:  Mrinalini Kulkarni; Peter D Reaven
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

3.  Early pre-diabetic state alters adaptation of myocardial glucose metabolism during ischemia in rats.

Authors:  Sandrine Morel; Corinne Berthonneche; Stéphane Tanguy; Marie-Claire Toufektsian; Pascale Perret; Catherine Ghezzi; Joël de Leiris; François Boucher
Journal:  Mol Cell Biochem       Date:  2005-04       Impact factor: 3.396

4.  Effects of a new advanced glycation inhibitor, LR-90, on mitigating arterial stiffening and improving arterial elasticity and compliance in a diabetic rat model: aortic impedance analysis.

Authors:  S Satheesan; J L Figarola; T Dabbs; S Rahbar; R Ermel
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

5.  The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study.

Authors:  Arwa Younis; Dana Eskenazi; Ronen Goldkorn; Jonathan Leor; Nili Naftali-Shani; Enrique Z Fisman; Alexander Tenenbaum; Ilan Goldenberg; Robert Klempfner
Journal:  Cardiovasc Diabetol       Date:  2017-05-22       Impact factor: 9.951

Review 6.  Mouse Models of Heart Failure with Preserved or Reduced Ejection Fraction.

Authors:  Natalie A Noll; Hind Lal; W David Merryman
Journal:  Am J Pathol       Date:  2020-04-25       Impact factor: 4.307

7.  Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome.

Authors:  Daad Hassan Akbar
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

8.  Haptoglobin genotype is a determinant of survival and cardiac remodeling after myocardial infarction in diabetic mice.

Authors:  Roy Asaf; Shany Blum; Ariel Roguin; Shiri Kalet-Litman; Jad Kheir; Avi Frisch; Rachel Miller-Lotan; Andrew P Levy
Journal:  Cardiovasc Diabetol       Date:  2009-06-02       Impact factor: 9.951

9.  Serum chemerin and high-sensitivity C reactive protein as markers of subclinical atherosclerosis in Egyptian patients with type 2 diabetes.

Authors:  Nagwa A Lachine; Abdel Aziz Elnekiedy; Magdy Helmy Megallaa; Gihane I Khalil; Mohamed A Sadaka; Kamel H Rohoma; Heba S Kassab
Journal:  Ther Adv Endocrinol Metab       Date:  2016-03-10       Impact factor: 3.565

10.  The bitter fate of the sweet heart: impairment of iron homeostasis in diabetic heart leads to failure in myocardial protection by preconditioning.

Authors:  Vladimir Vinokur; Eduard Berenshtein; Baruch Bulvik; Leonid Grinberg; Ron Eliashar; Mordechai Chevion
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.